Valera Pharmaceuticals, a fully-integrated specialty pharmaceutical company concentrating on the development and commercialization of products for the treatment of urological and endocrine conditions, diseases and disorders, filed for an initial public offering on Monday. In October 2004, the Food and Drug Administration approved the New Jersey-based pharmaceutical company to commercially sell and distributed Vantas, a 12-month implant for the palliative treatment of advanced prostate cancer that delivers histrelin, a lutenizing hormone-releasing hormone agonist, or LHRH agonist. The company has filed to be traded on the NASDAQ under the ticker symbol VLRX. UBS and Banc of America Securities are the lead underwriters on the deal.
